Evogene (EVGN) Competitors

$0.69 -0.03 (-3.68%)

Closing price 05/21/2026 04:00 PM Eastern

Extended Trading

$0.69 0.00 (-0.35%)

As of 08:22 AM Eastern

EVGN vs. CARM, SDST, TOMZ, SNES, and TSE

Should you buy Evogene stock or one of its competitors? MarketBeat compares Evogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evogene include Carisma Therapeutics (CARM), Stardust Power (SDST), TOMI Environmental Solutions (TOMZ), Senestech (SNES), and Trinseo (TSE).

How does Evogene compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk, media sentiment and profitability.

44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Carisma Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, Evogene has a beta of 1.39, meaning that its stock price is 39% more volatile than the broader market.

In the previous week, Evogene had 6 more articles in the media than Carisma Therapeutics. MarketBeat recorded 6 mentions for Evogene and 0 mentions for Carisma Therapeutics. Carisma Therapeutics' average media sentiment score of 0.00 beat Evogene's score of -0.50 indicating that Carisma Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Negative

Carisma Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 999,900.00%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Carisma Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Evogene	$3.85M	1.57	-$8.48M	-$1.17	N/A

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -638.12%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-638.12%	-142.00%	-73.79%

Summary

Carisma Therapeutics beats Evogene on 10 of the 16 factors compared between the two stocks.

How does Evogene compare to Stardust Power?

Stardust Power (NASDAQ:SDST) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stardust Power	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Evogene has higher revenue and earnings than Stardust Power. Stardust Power is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stardust Power	N/A	N/A	-$15.72M	-$2.00	N/A
Evogene	$3.85M	1.57	-$8.48M	-$1.17	N/A

Stardust Power has a net margin of 0.00% compared to Evogene's net margin of -638.12%. Stardust Power's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stardust Power	N/A	N/A	-161.57%
Evogene	-638.12%	-142.00%	-73.79%

Stardust Power has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Evogene has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

32.8% of Stardust Power shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 55.3% of Stardust Power shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Stardust Power and Stardust Power both had 6 articles in the media. Evogene's average media sentiment score of -0.50 beat Stardust Power's score of -0.50 indicating that Evogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stardust Power	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Evogene	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Evogene beats Stardust Power on 9 of the 13 factors compared between the two stocks.

How does Evogene compare to TOMI Environmental Solutions?

Evogene (NASDAQ:EVGN) and TOMI Environmental Solutions (NASDAQ:TOMZ) are both small-cap chemicals companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, media sentiment, dividends, risk, profitability and institutional ownership.

In the previous week, Evogene had 2 more articles in the media than TOMI Environmental Solutions. MarketBeat recorded 6 mentions for Evogene and 4 mentions for TOMI Environmental Solutions. TOMI Environmental Solutions' average media sentiment score of 0.95 beat Evogene's score of -0.50 indicating that TOMI Environmental Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
TOMI Environmental Solutions	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TOMI Environmental Solutions has higher revenue and earnings than Evogene. TOMI Environmental Solutions is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.57	-$8.48M	-$1.17	N/A
TOMI Environmental Solutions	$5.64M	3.02	-$3.75M	-$0.21	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
TOMI Environmental Solutions	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

10.4% of Evogene shares are owned by institutional investors. Comparatively, 4.8% of TOMI Environmental Solutions shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 23.5% of TOMI Environmental Solutions shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TOMI Environmental Solutions has a net margin of -75.34% compared to Evogene's net margin of -638.12%. Evogene's return on equity of -142.00% beat TOMI Environmental Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-142.00%	-73.79%
TOMI Environmental Solutions	-75.34%	-315.96%	-55.52%

Evogene has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, TOMI Environmental Solutions has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

Summary

TOMI Environmental Solutions beats Evogene on 9 of the 15 factors compared between the two stocks.

How does Evogene compare to Senestech?

Evogene (NASDAQ:EVGN) and Senestech (NASDAQ:SNES) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Evogene has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Senestech has a beta of 0.18, indicating that its stock price is 82% less volatile than the broader market.

Senestech has lower revenue, but higher earnings than Evogene. Senestech is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.57	-$8.48M	-$1.17	N/A
Senestech	$2.22M	4.27	-$6.38M	-$1.89	N/A

Senestech has a net margin of -304.22% compared to Evogene's net margin of -638.12%. Senestech's return on equity of -67.60% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-638.12%	-142.00%	-73.79%
Senestech	-304.22%	-67.60%	-49.21%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Senestech	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Senestech had 11 more articles in the media than Evogene. MarketBeat recorded 17 mentions for Senestech and 6 mentions for Evogene. Senestech's average media sentiment score of 0.23 beat Evogene's score of -0.50 indicating that Senestech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Senestech	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

10.4% of Evogene shares are owned by institutional investors. Comparatively, 5.2% of Senestech shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 2.2% of Senestech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Evogene and Senestech tied by winning 7 of the 14 factors compared between the two stocks.

How does Evogene compare to Trinseo?

Trinseo (NYSE:TSE) and Evogene (NASDAQ:EVGN) are both small-cap chemicals companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Trinseo presently has a consensus target price of $1.00, indicating a potential upside of 334.78%. Given Trinseo's higher probable upside, equities analysts clearly believe Trinseo is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinseo	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Evogene had 6 more articles in the media than Trinseo. MarketBeat recorded 6 mentions for Evogene and 0 mentions for Trinseo. Trinseo's average media sentiment score of 0.00 beat Evogene's score of -0.50 indicating that Trinseo is being referred to more favorably in the media.

Company	Overall Sentiment
Trinseo	Neutral
Evogene	Negative

Trinseo has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Evogene has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Evogene has lower revenue, but higher earnings than Trinseo. Evogene is trading at a lower price-to-earnings ratio than Trinseo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinseo	$3.13B	0.00	-$348.50M	-$11.55	N/A
Evogene	$3.85M	1.57	-$8.48M	-$1.17	N/A

Trinseo has a net margin of -13.15% compared to Evogene's net margin of -638.12%. Trinseo's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinseo	-13.15%	N/A	-11.72%
Evogene	-638.12%	-142.00%	-73.79%

82.7% of Trinseo shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 4.5% of Trinseo shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Trinseo beats Evogene on 9 of the 16 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.28M	$3.34B	$6.34B	$12.29B
Dividend Yield	N/A	2.29%	2.79%	5.33%
P/E Ratio	-0.50	18.53	20.85	25.52
Price / Sales	1.57	298.81	546.15	84.26
Price / Cash	N/A	129.82	44.13	56.16
Price / Book	0.51	6.92	10.04	7.01
Net Income	-$8.48M	$24.39M	$3.55B	$335.27M
7 Day Performance	-5.34%	2.10%	2.35%	1.16%
1 Month Performance	-14.40%	-1.75%	-0.55%	0.09%
1 Year Performance	-41.50%	62.17%	36.42%	34.54%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	0.9121 of 5 stars	$0.69 -3.7%	N/A	-41.5%	$6.28M	$3.85M	N/A	140	Earnings Report
CARM Carisma Therapeutics	2.2732 of 5 stars	$0.00 +50.0%	$1.00 +333,233.3%	-99.9%	$13K	$10.77M	0.00	20	Gap Up
SDST Stardust Power	0.2601 of 5 stars	$2.33 -2.1%	N/A	-61.4%	$23.72M	N/A	N/A	N/A	News Coverage
TOMZ TOMI Environmental Solutions	0.9234 of 5 stars	$0.78 -2.6%	N/A	-9.0%	$17.38M	$5.64M	N/A	20
SNES Senestech	2.2215 of 5 stars	$1.66 -4.0%	N/A	-31.7%	$9.11M	$2.22M	N/A	30	Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 5/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, SDST, TOMZ, SNES, and TSE

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to Stardust Power?

Summary

How does Evogene compare to TOMI Environmental Solutions?

Summary

How does Evogene compare to Senestech?

Summary

How does Evogene compare to Trinseo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, SDST, TOMZ, SNES, and TSE

How does Evogene compare to Carisma Therapeutics?

Do insiders and institutionals believe in CARM or EVGN?

Which has more risk & volatility, CARM or EVGN?

Does the media prefer CARM or EVGN?

Do analysts rate CARM or EVGN?

Which has better earnings & valuation, CARM or EVGN?

Is CARM or EVGN more profitable?

Summary

How does Evogene compare to Stardust Power?

Do analysts prefer SDST or EVGN?

Which has higher valuation & earnings, SDST or EVGN?

Is SDST or EVGN more profitable?

Which has more risk & volatility, SDST or EVGN?

Do institutionals and insiders have more ownership in SDST or EVGN?

Does the media refer more to SDST or EVGN?

Summary

How does Evogene compare to TOMI Environmental Solutions?

Does the media favor EVGN or TOMZ?

Which has higher earnings & valuation, EVGN or TOMZ?

Do analysts prefer EVGN or TOMZ?

Do institutionals & insiders hold more shares of EVGN or TOMZ?

Is EVGN or TOMZ more profitable?

Which has more volatility and risk, EVGN or TOMZ?

Summary

How does Evogene compare to Senestech?

Which has more risk and volatility, EVGN or SNES?

Which has higher earnings & valuation, EVGN or SNES?

Is EVGN or SNES more profitable?

Do analysts recommend EVGN or SNES?

Does the media favor EVGN or SNES?

Do insiders & institutionals believe in EVGN or SNES?

Summary

How does Evogene compare to Trinseo?

Do analysts rate TSE or EVGN?

Does the media refer more to TSE or EVGN?

Which has more risk and volatility, TSE or EVGN?

Which has higher earnings & valuation, TSE or EVGN?

Is TSE or EVGN more profitable?

Do institutionals & insiders believe in TSE or EVGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools